New Delhi (IANS) - There has been "significant price reduction" in major cancer and diabetic drugs over the past year as a measure of relief to patients in the country, the National Pharmaceutical Pricing Authority (NPPA) said. The drug prices regulator, in a tweet, said that since March 2016, there has been "significant price reduction" by up to 86% in some major cancer drugs, and by up to 42% in major diabetic drugs.
Among the major cancer drugs, the price of Iressa of Astrazeneca Pharma India, which cost Rs 29,259 (before revision), has been cut down by 86% to Rs 3,977.
The prices of other important cancer drugs, such as Nanoxel (Rs 1,035) and Frastim (Rs 1,273) have been slashed by 55% and 51% respectively.
In terms of diabetic drugs, Glypride by Sun Pharmaceuticals has been priced at Rs 53 - down 42% from Rs 91.
As per the NPPA, other pharma firms whose drug prices have been revised downwards are Dr Reddy's Lab, Abbot Healthcare, Micro Labs, Dabur India, Lupin and others.